All articles tagged with #lenacapavir
South Africa, Eswatini, and Zambia have begun using a groundbreaking HIV prevention injection, lenacapavir, which reduces transmission risk by over 99.9% and is administered twice a year, marking a significant advancement in HIV prevention efforts in Africa, though access and cost remain challenges.
Zimbabwe is set to be among the first countries to roll out lenacapavir, a groundbreaking twice-yearly HIV prophylactic, which has shown over 99% efficacy in trials and is hailed as a potential 'miracle drug' in HIV prevention, though concerns about cost and accessibility remain.
South Africa's health minister announced the introduction of lenacapavir, the world's first twice-yearly HIV prevention injection, with an initial limited supply of nearly half a million doses starting in April 2026, amid concerns over funding cuts and licensing issues affecting local manufacturing and access.
A new drug called lenacapavir, approved for HIV prevention, offers a twice-yearly injection with near-vaccine efficacy, potentially transforming HIV prevention efforts worldwide, especially in low-income countries, but its impact will depend heavily on political and logistical factors.
Jamaica is considering a pilot program for the FDA-approved injectable HIV drug lenacapavir, which could significantly improve adherence and prevention efforts, especially among young people, with plans for free access in the public health system and potential scaling up based on pilot outcomes.
A new twice-yearly HIV prevention injection, lenacapavir, is set to be more affordable and accessible in resource-limited countries like Nigeria, sparking mixed reactions due to skepticism and conspiracy theories, despite potential benefits in reducing HIV transmission and improving adherence.
A new HIV prevention drug, Lenacapavir, will be made available at a drastically reduced cost of $40 in over 100 low- and middle-income countries by 2027, potentially transforming HIV prevention efforts worldwide and helping to curb the epidemic.
Cheap supplies of the groundbreaking HIV prevention injection lenacapavir will be available in many poorer countries from 2027 at $40 per patient per year, potentially transforming efforts to end the global HIV epidemic, with support from major health organizations and generic drug manufacturers.
The CDC strongly recommends the use of injectable lenacapavir, administered every 6 months, as an effective and safe option for HIV preexposure prophylaxis in persons weighing at least 35 kg, based on high-certainty evidence from clinical trials showing near 100% efficacy in preventing HIV infection.
The U.S. announced support for lenacapavir, a groundbreaking HIV prevention drug requiring only biannual injections, aiming to reach 2 million people by 2028 and significantly impact the global HIV epidemic, especially in low- and middle-income countries.
The U.S. Department of State announced a PEPFAR initiative to bring Gilead Sciences' breakthrough HIV drug lenacapavir to high-burden countries, aiming to reach up to 2 million people by 2028. The twice-yearly injectable medication, which has shown over 99% effectiveness in clinical trials, will be distributed with the support of the U.S. government and the Global Fund, at no profit from Gilead, to help prevent mother-to-child transmission and reduce HIV infections globally.
The European Medicines Agency has recommended approval for lenacapavir, a twice-yearly injectable drug that could significantly reduce HIV transmission, with potential to help end the epidemic if widely accessible. The drug, already used to treat HIV, has shown nearly 100% effectiveness in preventing transmission in studies and is the longest-lasting prevention option available. While Gilead plans to produce affordable generics for 120 poor countries, concerns remain about limited availability in regions like Latin America, risking missed opportunities to curb global HIV spread.
The European Medicines Agency recommends approval of lenacapavir, a twice-yearly injectable drug that could significantly help prevent HIV transmission, with potential global impact if widely accessible, especially in high-risk and resource-limited settings.
The World Health Organization now recommends the use of lenacapavir, a long-acting injectable drug administered twice a year, as part of HIV prevention strategies, especially for high-risk groups, marking a significant shift from daily pills to less frequent, more convenient options amid funding challenges for HIV programs.
WHO recommends offering long-acting injectable lenacapavir (LEN) as an additional HIV prevention option, administered twice a year, to increase PrEP uptake and effectiveness. The guideline emphasizes using rapid diagnostic tests for individuals on injectable PrEP like LEN and cabotegravir, promoting flexible testing approaches to ensure access and continuation of PrEP, and highlights the need for further research, including HIV self-testing for long-acting injectable PrEP.